Inversely, targeted anti-RSPO3 treatment in a PTPRK-RSPO3 xenograft CRC model was shown to induce tumor differentiation whilst reducing growth, stem cell marker expression and canonical Wnt pathway activity [58]. The gene discussed is PTPRK; the disease is neoplasm.